P440: Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology
ECCO '19 Copenhagen
2019
P441: Long-term immunogenicity of vedolizumab in ulcerative colitis and Crohn’s disease (GEMINI Programme)
ECCO '19 Copenhagen
2019
P442: Strictureplasty for Crohn’s disease of the small bowel in the biological era: long-term outcomes and risk factors for site specific recurrence
ECCO '19 Copenhagen
2019
P443: Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)
ECCO '19 Copenhagen
2019
P444: Post-induction Infliximab trough levels in severe and moderate paediatric ulcerative colitis: preliminary data of a retrospective, population cohort-based study
ECCO '19 Copenhagen
2019
P445: Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
ECCO '19 Copenhagen
2019
P446: Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience
ECCO '19 Copenhagen
2019
P447: The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P448: Cannabis and cannabinoids for the treatment of inflammatory bowel disease: a systematic review and meta-analysis
ECCO '19 Copenhagen
2019
P449: Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial
ECCO '19 Copenhagen
2019
P450: Association of Infliximab trough levels and transmural healing in Crohn’s disease
ECCO '19 Copenhagen
2019
P451: Safety and efficacy of ferric carboxymaltose (FCM) for the treatment of iron deficiency anaemia in paediatric patients affected by inflammatory bowel disease (pIBD)
ECCO '19 Copenhagen
2019
P452: Impact of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: accessibility, resource utilisation and outcomes
ECCO '19 Copenhagen
2019
P453: Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany
ECCO '19 Copenhagen
2019
P454: Prediction of endoscopic activity in patients with Crohn’s disease: systematic review and external validation of published prediction models
ECCO '19 Copenhagen
2019
P455: Evaluation of the optic nerve function in patients with ulcerative colitis and Crohn’s disease
ECCO '19 Copenhagen
2019
P456: Quality of life is associated with wearable-based physical activity in patients with inflammatory bowel disease: a prospective, observational study
ECCO '19 Copenhagen
2019
P457: Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
ECCO '19 Copenhagen
2019
P458: Effect of cognitive behavioural therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomised trial
ECCO '19 Copenhagen
2019
P459: Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience
ECCO '19 Copenhagen
2019